Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантарис Фарма А/СfiledCriticalСантарис Фарма А/С
Priority claimed from PCT/DK2008/000344external-prioritypatent/WO2009043353A2/en
Publication of UA102529C2publicationCriticalpatent/UA102529C2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
Double-stranded ribonucleic acids (dsrna) for inhibiting expression of transthyretin (ttr), pharmaceutical compositions comprising them and use thereof in the treatment of disorders mediated by ttr expression
COMPOUNDS DERIVED FROM QUINAZOLINA SUBSTITUTES, INHIBITORS OF QUINASA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, ATEROSCLEROSIS AND ARTHRITIS.
MACROCICLICAL COMPOUNDS DERIVED FROM 6-ARIL-4-MERCAPTO- [1.3.5] TRIAZINA / [1.3] PIRIMIDIN-2-AMINA; PHARMACEUTICAL COMPOSITION, USEFUL IN THE TREATMENT OF CANCER.
Derivatives of 1h-benzoimidazol-2-yl-propyl-methyl-amino-ethyl-5-aryl-bicyclo[2.2.2]oct-5-en-2-ol, pharmaceutical compositions comprising them and their use in the manufacture of medicaments